PNC Financial Services Group Inc. Acquires 6,381 Shares of Haleon plc (NYSE:HLN)

PNC Financial Services Group Inc. grew its stake in Haleon plc (NYSE:HLN) by 3.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 211,326 shares of the company’s stock after purchasing an additional 6,381 shares during the period. PNC Financial Services Group Inc.’s holdings in Haleon were worth $2,236,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Clearbridge Investments LLC grew its position in Haleon by 8.6% during the second quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock worth $344,888,000 after buying an additional 3,307,009 shares in the last quarter. Sculptor Capital LP raised its stake in shares of Haleon by 67.8% in the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock valued at $73,407,000 after purchasing an additional 3,592,000 shares in the last quarter. Douglas Lane & Associates LLC lifted its position in Haleon by 1.6% in the second quarter. Douglas Lane & Associates LLC now owns 8,533,768 shares of the company’s stock worth $70,489,000 after purchasing an additional 131,892 shares during the period. Envestnet Asset Management Inc. boosted its stake in Haleon by 2.7% during the second quarter. Envestnet Asset Management Inc. now owns 7,572,548 shares of the company’s stock worth $62,549,000 after buying an additional 196,843 shares in the last quarter. Finally, Raymond James & Associates increased its holdings in Haleon by 14.7% in the 2nd quarter. Raymond James & Associates now owns 4,019,978 shares of the company’s stock valued at $33,205,000 after buying an additional 515,651 shares during the period. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

NYSE:HLN opened at $9.58 on Tuesday. The stock has a market capitalization of $43.37 billion, a P/E ratio of 28.18, a price-to-earnings-growth ratio of 2.91 and a beta of 0.30. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The firm has a 50 day moving average of $10.01 and a 200-day moving average of $9.39.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. UBS Group raised Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Morgan Stanley boosted their price target on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research note on Friday, September 20th. Finally, Berenberg Bank began coverage on Haleon in a research note on Tuesday, August 6th. They set a “buy” rating for the company. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.